Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $85.46 million. The enterprise value is -$57.31 million.
Important Dates
The last earnings date was Thursday, March 27, 2025, after market close.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ORMP has 40.31 million shares outstanding. The number of shares has increased by 0.65% in one year.
| Current Share Class | 40.31M |
| Shares Outstanding | 40.31M |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | -0.56% |
| Owned by Insiders (%) | 14.06% |
| Owned by Institutions (%) | 13.10% |
| Float | 32.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.60 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.19, with a Debt / Equity ratio of 0.00.
| Current Ratio | 25.19 |
| Quick Ratio | 24.97 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.98 |
Financial Efficiency
Return on equity (ROE) is -12.39% and return on invested capital (ROIC) is -4.43%.
| Return on Equity (ROE) | -12.39% |
| Return on Assets (ROA) | -4.25% |
| Return on Invested Capital (ROIC) | -4.43% |
| Return on Capital Employed (ROCE) | -8.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.47M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $3.18 million in taxes.
| Income Tax | 3.18M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.63% in the last 52 weeks. The beta is 1.61, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -21.63% |
| 50-Day Moving Average | 2.30 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 41.96 |
| Average Volume (20 Days) | 122,598 |
Short Selling Information
The latest short interest is 664,591, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 664,591 |
| Short Previous Month | 616,037 |
| Short % of Shares Out | 1.65% |
| Short % of Float | 2.08% |
| Short Ratio (days to cover) | 3.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.78M |
| Pretax Income | 10.46M |
| Net Income | -19.06M |
| EBITDA | -12.59M |
| EBIT | -12.78M |
| Earnings Per Share (EPS) | -$0.48 |
Full Income StatementBalance Sheet
The company has $141.93 million in cash and $372,000 in debt, giving a net cash position of $141.56 million or $3.51 per share.
| Cash & Cash Equivalents | 141.93M |
| Total Debt | 372,000 |
| Net Cash | 141.56M |
| Net Cash Per Share | $3.51 |
| Equity (Book Value) | 145.35M |
| Book Value Per Share | 3.66 |
| Working Capital | 137.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.41 million and capital expenditures -$18,000, giving a free cash flow of -$8.43 million.
| Operating Cash Flow | -8.41M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -8.43M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |